**CURRICULUM VITAE**

**Education:**

B.A. University of Rochester (Biology; Religion & Classics) 1994

M.D. University of Rochester School of Medicine and Dentistry 1998

**Career/Academic Appointments:**

1998-99 Intern, Primary Care Medicine Program, Yale University School of Medicine

1999-00 Postdoctoral Fellow, Schizophrenia Research Clinic, Yale University

2000-03 Psychiatry Resident, Dept. of Psychiatry, Yale University School of Medicine

2003-05 Fellow, Yale-West Haven VA Schizophrenia Research Program

2005-11 Assistant Professor, Dept. of Psychiatry, Yale University

2005-present Staff Psychiatrist, Ambulatory Services, Connecticut Mental Health Center

2011-19 Associate Professor, Dept. of Psychiatry, Yale University School of Medicine

2013-14 Visiting Associate Professor, Harvard Medical School, Boston, MA

2019-present Professor, Dept. of Psychiatry, Yale University School of Medicine

**Administrative Positions:**

2006- present Director, Program for Specialized Treatment Early in Psychosis (STEP)

2009-19 Associate Training Director, Yale Psychiatry Residency Program

**Board Certification:**

American Board of Psychiatry and Neurology: Diplomate (renewed 2017-)

**Professional Honors & Recognition:**

**International/National/Regional**

2015 Global Organization of People of Indian Origin (CT) Annual Award for *Contributions to Medicine*.

2011 *Model Curriculum* in Evidence-Based Mental Health, American Association of Directors of Psychiatry Residency Training (AADPRT)

2010 Harvard-Macy Institute Scholar

**University**

2018 Stephen Fleck Award. *For an individual who represents the highest standards as a clinician and educator.* Dept. of Psychiatry, Yale University School of Medicine

2017-19 Yale Medicine Emerging Leaders Program, Yale School of Management

2011 Teaching Award, Yale Psychiatry Residents Association.

2010 Faculty Travel Award, Yale Global Health Initiative,

2010 Inaugural Clinical Innovations in Psychiatry Award (2nd place), Dept. of Psychiatry, Yale University School of Medicine

2009 Yale Medical School nominee for Robert Wood Johnson Foundation Physician Faculty Scholars Program

2007 Chairman’s Award. *For outstanding clinical, teaching and administrative contributions.* Dept. of Psychiatry, Yale University School of Medicine

2004 Resident Teaching Award. Dept. of Psychiatry, Yale University School of Medicine

**Grant/Clinical Trials History:**

**Current Grants**

Title: Double Blind, Randomized, Placebo-Controlled study of MitoQ as adjunctive treatment for patients with early-phase schizophrenia-spectrum disorder and mitochondrial dysfunction

Major Goals: To investigate the role of oral administration of MitoQ on neurocognition, psychiatric symptoms, functioning, exosome levels of the mechanism-based biomarkers miR-137 and COX6A2 in HRHR as compared to LR in the early phase of illness.

Status of Support: Pending IRB approval

Project Number: Pending

Name of PD/PI: Srihari, Vinod

Per cent effort: 5%

Source of Support: Stanley Foundation

Project/Proposal Start and End Date: 08/01/2024-04/30/2026

Total Award Amount (including Indirect Costs): $351,038

Agency: National Institute of Mental Health/NIH/DHHS

Project Number: 5R01MH127158-02

Title: 3/5 Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS)

Major Goals: In this proposal, we will characterize the trajectories of outcome in early course psychotic disorders treated in coordinated specialty care programs. We will also identify clinical and biological features, and biological subtypes of psychotic disorders that may help predict outcome.

Name of PD/PI: Pearlson, Godfrey D

Role: co-I

Per cent effort: 5%

Project Period: 08/15/2022 - 06/30/2027

Total Award Amount (including Indirect Costs): $1,466,668

Agency: National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS

Project Number: 1R21EB033911-01A1

Name of PD/PI: Kumaragamage, Chathura

Title: Robust and highly selective proton MRSI on a clinical 3 T system using a second order gradient insert, for application in schizophrenia

Major Goals: Magnetic Resonance Spectroscopic Imaging (MRSI) is a valuable and complementary modality to MRI, that can detect glutamate dysfunction by mapping glutamate and glutamine levels in the brain. Alterations in the glutamatergic system have been implicated in a variety of brain diseases such as schizophrenia, though the application of MRSI to schizophrenia and other disorders has been hampered by skull lipid contamination preventing reliable measurements in critical regions such as the frontal cortex. The significance of this proposal is that we will develop and validate novel MRSI methods on a clinical 3 T MRI system that largely eliminate lipid contamination allowing high quality maps of glutamate and glutamine levels throughout the frontal lobe and other brain regions, and evaluate tolerance and translatability of the methods on a clinical cohort of patients.

Role: co-I

Per cent effort: 5%

Project Period: 09/21/2023 - 09/20/2025

Total Award Amount (including Indirect Costs): $460,625

Agency: National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS

Project Number: 1R01EB034720-01

Title: An integrative Bayesian approach for linking brain to behavioral phenotype

Name of PD/PI: Constable, Todd

Major Goals: This project is aimed at developing a novel approach to building generalizable models that identify the network level functional organization in the brain associated with clinical symptoms and behavior. Understanding the organizing principles of the brain as they relate to specific psychiatric symptoms and cognitive behaviors will improve diagnoses, aid in categorizing patients, identify treatment targets, allow assignment of the correct treatment to patients, and provide a quantitative means of monitoring treatment response. This work could have a major impact on the application of functional MRI in both basic neuroscience and psychiatric medicine.

Project Period: 08/01/2023 - 07/31/2027

Role: co-I

Per cent effort: 3%

Total Award Amount (including Indirect Costs): $2,431,597

Agency: Independent Research Fund Denmark, Danish Agency for Science and Higher Education

Title: Duration of untreated psychosis revisited – testing the effect of early detection services on the duration of untreated psychosis. TOPUS

Role: Consultant

Project Period: TBD

Total Award Amount (including Indirect Costs): TBD

Agency: NIH

I.D.#: U01MH124639-01

Title: ProNET: Psychosis-Risk Outcomes Network

Major Goals: Our 26 international sites will recruit 1040 CHR and follow them with clinical and biomarker assessments over two years, along with 260 healthy controls assessed at baseline. In partnership with the Data Processing, Analysis, and Coordinating Center, we will contribute to analyses to dissect the heterogeneity of CHR and develop tools for outcome definition and patient stratification.

P.I.: Woods/Bearden/Kane (MPI)

Role: Co-I

Per cent effort: 5%

Project Period: 09/01/20-08/31/25

Total Award Amount (including Indirect Costs): $59,002,431

Agency: NIH

Title: Academic-Community EPINET (AC-EPINET): Mitigating Barriers to Care

Major Goals: Yale University will perform a needs assessment of the clinical sites, implement, offering hosting and maintenance of the CSC-ONE platform. Periodic (at least bi-annual) review of performance and determination of further development of the workflow/software will be performed.

I.D.#: R01 – RFA-MH-20-205

P.I.: Breier

Role: Co-I

Per cent effort: 10%

Project Period: 09/01/20-08/31/24

Total Award Amount (including Indirect Costs): $779,899

Source of Support: Connecticut Dept. of Mental Health and Addiction Services

Title: STEP FEP (block) FY2024

Major Goals: Serving the DMHAS population, leads activities that connect this research to the missions of delivering a model service (the STEP Clinic), disseminating clinical best practices (via Learning Health Networks), education and workforce development and influencing policies that support the public health mission of early Intervention for schizophrenia spectrum disorders.

Project Number: 23MHA60004

Name of PD/PI: Sernyak, Michael (award PI) Srihari, Vinod, Grant PI

Per cent effort: 50%

Project/Proposal Start and End Date: 7/01/2023 -

Total Award Amount (including Indirect Costs): $22,080,244

Agency: Substance Abuse and Mental Health Services Administration (SAMHSA)

I.D.: #1 H79 SM081190-01

Title: PRIME Clinic: Stepped Care for Youth and Young Adults at Clinical High Risk for Psychosis.

P.I.: Scott Woods/ Julienne Giard (DMHAS)

Role on project: Co-Investigator

Percent effort: 5%

Direct costs per year: $275,000

Total costs for project period: $ 1,073,084

Project period: 09/30/2018 –

**Past Grants**

Agency: NIH/NIMH

I.D.# R01MH121095

Title: AN INDIVIDUALIZED, MULTIDIMENSIONAL DIMENSIONAL APPROACH TO PSYCHOPATHOLOGY

P.I.: Todd Constable, PhD

Role on Project: Co-Investigator

Percent effort: 15%

Direct costs per year: $498,853

Total costs for project period: $4,191,895

Project period: 08/1/2019-05/31/2024

Agency: NIH/NIMH

I.D.# R01MH121095

Title: EARLY-PHASE SCHIZOPHRENIA: PRACTICE-BASED RESEARCH TO IMPROVE TREATMENT OUTCOMES (ESPRITO)

P.I.: Delbert Robinson, MD/ John Kane, MD

Role on Project: Co-Investigator

Percent effort: 3%

Direct costs per year: $1,167,542

Total costs for project period: $ 7,660,197

Project period: 08/22/2019-05/31/2024

Agency: NIMH

I.D.#: 1U01MH121766-01

Title: A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia

P.I.: Anticevic/Krystal

Role on Project: Co-Investigator

Per cent effort: 5%

Total costs for project period: $3,202,913

Project Period: 09/23/2019 – 08/31/2022

Agency: Department of Children and Families (DCF)

I.D.#: 20DCF6912AA

Title: First Episode Psychosis/Clinical High Risk for Psychosis (FEP/CHRP) initiative

P.I.: Vinod Srihari, M.D.

Per cent effort: 10%

Direct costs per year: $43,478

Total costs for project period: $50,000

Project Period: 10/1/19 -12/30/20

Agency: NIH/NIMH

I.D.# R01MH112887

Title: Predictive coding as a framework for understanding psychosis.

P.I.: Jim Gold/ Philip Corlett

Role on Project: Co-Investigator

Percent effort: 1%

Direct costs per year: $ $195,426

Total costs for project period: $ $287,276

Project period: 12/1/2017-10/31/2022

Agency: Yale Global Mental Health Program

I.D.# Yale Global Mental Health Grant

Title: Investigating the Duration of Untreated Psychosis in Jamaica

P.I.: Flavia DeSouza (PGY2 resident)

Role on Project: Mentor

Percent effort: N/A

Direct costs per year: $5,000

Total costs for project period: $5,000

Project period: 04/01/2018-03/31/2019

Agency: NIH/NIMH

I.D.# R01MH103831

Title: “STEP-ED: Reducing Duration of Untreated Psychosis and its Impact in the U.S.”

P.I.: Vinod H. Srihari, M.D.

Percent effort: 25%

Direct costs per year: $639,651

Total costs for project period: $3,690,680

Project period: 09/26/2013 – 08/31/2018 (NCE until 8/31/2019)

Agency: NIH/NIMH

I.D.# R01MH107426

Title: “Multi-model Assessment of Social Process Systems across Neurodevelopmental Disorders.”

P.I.: James McPartland Ph.D./ Vinod H. Srihari, M.D.

Role on Project: (Multiple) P.I.

Percent effort: 5%

Total costs for project period: $650,980

Project period: 07/15/2015 – 05/31/2018

Agency: NIH/NIDDK

I.D.# R01 DK93924-01A1

Title: “Naltrexone for Antipsychotic-induced Weight Gain”

P.I.: Cenk Tek, M.D.

Role on Project: Co-investigator

Percent effort: 1%

Total costs for project period: $2,296,341

Project period: 03/01/13 - 02/28/18

Agency: Donaghue Foundation

I.D.# R3: Making Research Relevant & Ready

Title: “STEPping Out: supporting the dissemination of STEP care using an outcomes-based care management tool and online community”

P.I.: John Cahill M.D./ Vinod H. Srihari

Role on Project: Senior P.I.

Percent effort: 1%

Total costs for project period: $55,000

Project period: 09/15/2015 – 03/14/2017

Agency: NIH/NIMH

I.D.# R01MH103831-03S1 (supplement)

Title: “Developing inflammatory biomarkers for early intervention in psychosis.”

P.I.: Vinod H. Srihari, M.D.

Percent effort: 5%

Total costs for project period: $232,165

Project period: 09/01/2015 – 08/31/2016

Agency: SAMHSA

Title: “Specialized Crisis Intervention Training for Young Adults (SCYA)”

P.I.: Miriam Delphin-Rittmon, Ph.D.

Role on Project: Consultant

Project period: 10/1/13-10/30/16

Agency: NIH/NIMH

I.D.# RC1MH088971-01

Title: “STEP: A Community Health Center Based Cost Effectiveness Study”

P.I.: Vinod H. Srihari, M.D.

Percent effort: 10%

Total costs for project period: $749,840

Project period: 09/25/09-05/31/13

Agency: The Donaghue Foundation

I.D.# DF07-014

Title: “STEP: A Community Health Center Based Cost Effectiveness Study”

P.I.: Vinod H. Srihari, M.D.

Percent effort: 5%

Total costs for project period: $243,568

Project period: 7/1/07 - 6/30/10

Agency: The CMHC Foundation

Title: “A qualitative study of pathways to and through care in patients with psychotic illness”

P.I.: Gerritt van Schalkwyk, MBBS

Role on Project: Mentor

Percent effort: N/A

Total costs for project period: $3,000

Project period: 7/1/2013- 6/31/14

**Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale:**

**International/National**

2024 University of Washington Dept of Psychiatry and Behavioral Sciences, Chad Crooks Inaugural Annual Grand Rounds, “Bringing Best and Innovative Practices in Early Detection of Psychosis to Washington”

 Indiana Department of Mental Health Services, invited speaker, “Building Systems of Care for Schizophrenia Spectrum Disorders: The STEP Program.”

2023 National Alliance for Mental Illness, invite speaker (webinar), “Building a Statewide Learning Healthcare System in CT”

2022 Creighton University, Dept. of Psychiatry Grand Rounds. “Building a population health based system of care for psychotic disorders.”

 Indiana University, Dept. of Psychiatry Grand Rounds. “Reducing the Duration of Untreated Psychosis (DUP).”

2021 Massachusetts M-COPE meeting on Early Detection of Schizophrenia spectrum disorders.

 NRI/NASHMPD webinar “Early Detection in a U.S. Community.”

 PEPPNET Webinar “Reducing DUP in a U.S. Community: The Mindmap Campaign”

 Connecticut Early Psychosis Learning Health Network, ECHO case conference: “Medication treatment in early psychosis.”

2020 MAPNET Webinar “Reducing DUP in a U.S. Community: The Mindmap Campaign”

 NAMI-CT Annual Conference “Providing care for early psychosis in a pandemic.”

 TENNESSEE ASSOCIATION OF MENTAL HEALTH ORGANIZATIONS (TAMHO) Early Episode Psychosis Conference

 Ohio State University Department of Psychiatry, Virtual Speaker Series. Early Intervention for Schizophrenia: Building Systems of Care for Knowledge Translation

2019 Grand Rounds, Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, Akron, OH. “Population Health based services for Psychotic Disorders.”

2018 Graduation speaker, Psychiatry Residency, Northwell Health at The Zucker Hillside Hospital

2017 Invited speaker, Congressional Briefing, hosted by National Alliance on Mental Illness (NAMI), U.S. Capitol, Washington D.C. “Science to Service: Early Intervention Services for Psychotic Disorders.”

Invited speaker, BIDMC/MMHC/Harvard Medical School Conference on Responding to Risk for Psychosis Among College Students: Tools for Early Engagement, Assessment, and Treatment, Boston, MA. “Early Intervention Turns the Tide.”

Invited Speaker, NIMH/SAMHSA conference on Harmonizing Clinical Data Collection in Community-Based Treatment Programs for First Episode Psychosis, Rockville, MD. “The STEP Program: A regional model for a national Learning Healthcare Network.”

Invited Guest, Where We Live, NPR/WSHU: Write On! Encouraging Young Adults To Share Stories, Confront Mental Health Stigma. <https://www.wnpr.org/post/write-encouraging-young-adults-share-stories-confront-mental-health-stigma>

2016 Invited speaker, Xiangya Hospital, Changsha, Hunan Province, China. “Building a Population Health System of care for Psychotic Disorders.”

 Keynote speaker, Yale-China Fellowship Annual Conference, Kunming, Yunnan Province, China. “Reducing Duration of Untreated Psychosis (DUP).”

Invited speaker, NIMH Outreach Partnership Program 2016 Annual Meeting, Bethesda, MD. “STEP-ED: Reducing Duration of Untreated Psychosis and its Impact in the U.S. (R01MH103831)”

2015 Webinar faculty, National Association of State Mental Health Program Directors (NASMHPD) Technical Assistance program: “Population Health based approaches to early intervention for psychotic disorders.” [Web link](http://www.nasmhpd.org/content/methodological-and-practical-issues-population-based-programming-incidence-engagement)

 Webinar faculty, Residency Seminar, Duke University, Durham, NC: “Review of STEP’s first US based RCT of first-episode services.”

Grand Rounds, Tulane University Dept. of Psychiatry, New Orleans, LA: “Early Intervention in the U.S. Public Sector”

2014 Plenary speaker, 5th International Conference on Schizophrenia Research (ICONS), Chennai, India: “Early Detection of Psychosis in the U.S. Public Sector.”

 Keynote speaker, 20th Schizophrenia Days conference, University of Stavanger, Stavanger, Norway. “The STEP-ED study: Adding Early Detection to a First-Episode Services in the U.S. Public Sector.”

2013 Harvard-Longwood Psychiatry Grand Rounds, Boston, MA: “The STEP-ED Trial: Reducing the Duration of Untreated Psychosis and its impact in the U.S.”

 Schizophrenia Research Foundation (SCARF), Chennai, India: “Mental Health Services for Emerging Adults Refine or Re-engineer? A case study from Connecticut, U.S.A.”

 Forum on Serious Mental Illness in the Emerging Adult at Mississippi State University, USA. “Mental Health Services for Emerging Adults: Refine or Re-engineer?”

2012 5th International Conference on Schizophrenia Research (ICONS) of the Schizophrenia Research Foundation (SCARF), Chennai, India: “Delivering an Early Intervention Service in a U.S. community setting.”

 UCSF Department of Psychiatry, San Francisco, CA. Grand Rounds: “Building Psychiatrists.”

2011 Invited presenter, Schizophrenia CME E-Journal Club (Webinar hosted by Dr. John Kane, Professor, Albert Einstein College of Medicine): “Cardiovascular Risk in First-Episode Psychosis.”

 Indian Global Psychiatric Initiative (IGPI) Annual Conference, New Delhi, India: “Service delivery for Early Psychosis and the Indian Context.”

 Harvard-Longwood Psychiatry Grand Rounds, Boston, MA: “STEPping up: Early Intervention for Psychosis in the U.S. Public Sector”

2010 Acadia Hospital, Maine, AWARE Conference on Early Detection, Characteristics and Treatment of Psychosis: “The STEP Program.”

2005-09 Invited core faculty, Annual international Teaching Evidence-Based Medicine (TEBM) workshop, Center for Evidence-Based Medicine, University of Oxford, Oxford, U.K.

**Regional**

2022- >30 presentations on a variety of topics related to the care of early psychosis patients as part of an ECHO model of workforce development hosted by the STEP Program for Connecticut practitioners (social workers, nurses, psychologists and psychiatrists).

2024 Yale Psychiatric Hospital, Staff & Resident Meeting, “Antipsychotic Rx for Early Course Schizophrenia spectrum Disorders.”

2023 Yale Conference on Mental Illness, Yale School of Management, Invited Plenary Speake. “Building Systems of Care for Schizophrenia Spectrum Disorders: The STEP Program.”

 Ohio Mental Health Services (OMHAS), invited speaker, Services Leadership Meeting: “Building a Learning Health Network for First-Episode Psychosis in Ohio.”

2022 Connecticut Adult Mental Health Planning Council, Department of Mental Health and Addiction Services (DMHAS), invited speaker, “Disseminating Early Intervention Services for Schizophrenia Spectrum Disorder in CT.”

2013-‘19 >50 presentations to a range of stakeholders as part of NIH funded public education campaign to shorten delays to care for early psychosis. Specifically, members of the following groups in 10 surrounding towns of target catchment have either invited me to present or been present at several workshops I have hosted in the area: Police departments, College/School counseling and academic staff, Clergy, Consumer/youth groups, State government executive and legislative policy staff, adult and pediatric primary care clinicians (nursing, social work and physicians)

2019 Moderator, NAMI Connecticut Annual Conference, Southbury, CT. Panel with Commissioners of Department of Mental Health and Addiction Services (DMHAS) and Department of Children and Families (DCF).

 Invited speaker, Community Health Center Association of Connecticut (CHACT), 2019 Community Health Summit, Wallingford, CT. “Building Population Based Early Intervention Services for Connecticut.”

 Invited speaker, New England Network for First-Episode Psychosis, SAMHSA technical assistance initiative, Westford, MA. “First Episode Psychosis: The What, How, and Why of Implementing Evidence-Based Practice.”

2018 Invited speaker, Connecticut Department of Children and Families & Department of Mental Health and Addiction Services hosted forum on Early Intervention for Connecticut community agencies, Rocky Hill, CT. “Building Population Health Systems of care for Psychotic Disorders in Connecticut.”

 Pre-conference workshop 11th International Conference on Early Intervention in Mental Health, International Early Psychosis Association (IEPA), Boston, US. Expert panel: ‘Coordinated Specialty Care – a team approach.’

2017 Invited speaker, Joint Behavioral Council of Connecticut, Department of Mental Health and Addictions Services (DMHAS), Middletown, CT. “Building Population Health Systems of care for Psychotic Disorders in Connecticut.”

Invited speaker, NAMI Connecticut Annual Conference, Middletown, CT. “Building a Population Health system for Connecticut.”

2016 Keynote speaker, Annual Brain Dance Awards and Grand Rounds, Institute of Living, Hartford, CT. “The Mindmap Campaign and Population Based Systems of Care for Psychosis”

2015 Invited speaker, Annual Meeting, National Alliance for the Mentally Ill (NAMI), Hartford, CT: “Building a Population-Based System of Care for Psychosis: The STEP Program”

2014 Evidence-Based Practices Committee, Department of Mental Health and Addictions Services (DMHAS), Middletown, Connecticut. “Early Intervention for Psychotic Disorders in the U.S. Public-Sector: The STEP Clinic**.**”

 Continuing Education Seminar, Hill Health Center, New Haven, CT: “Reducing the Duration of Untreated Psychosis in Connecticut.”

 Multiple presentations to Crisis Intervention Teams (CIT) in Connecticut: “Encountering the Young patient with a psychotic disorder.”

2013 Invited testimony to the Governor’s (Sandy Hook) Advisory Commission, Connecticut. “Improving Youth Mental Health Services in Connecticut: Refine or Re-engineer?”

Danbury Hospital, CT, Grand Rounds: “Early Intervention for Psychotic Disorders.”

University of Connecticut, Storrs, CT. “STEP-ED: Reducing Duration of Untreated Psychosis and its impact in the U.S.”

National Alliance on Mental Illness (NAMI), Annual Conference, Connecticut chapter. “Improving Mental Health Services in Connecticut.”

2010 Annual Meeting featured speaker, Southwest Regional Mental Health Board, Westport, CT: “Early Intervention for Schizophrenia in Connecticut.”

 Continuing Professional Development seminar, Hill Health Center, New Haven, CT: “Early Intervention services for Psychosis in Connecticut.”

 Continuing Professional Development seminar, Cedarhurst School, Hamden, CT: “Early identification and treatment for serious mental illnesses.”

 Continuing Professional Development seminar, Dixwell-Newhallville Community Mental Health Services, New Haven, CT: "Research Oriented Practice: Learning and Doing."

2007 Early Interventions for Psychosis, Annual conference of the National Alliance on Mental Illness (NAMI) Hartford, CT.

2005 Continuing Professional Development seminar, Counseling Services, Southern Connecticut State University, New Haven, CT: “Early Interventions for Psychosis.

**Peer-Reviewed Presentations & Symposia Given at Meetings Not Affiliated with Yale:**

**International/National**

2023 Symposium, International Early Psychosis Association (IEPA), Lausanne, Switzerland. “DUP reduction in the US and a replication of the Scandinavian TIPS project”.

2021 Symposium, Schizophrenia International Research Society (SIRS), Florence: “Layers of the Real World? the External Validity of Early Psychosis Research and Implications for Population Health” (In person conference canceled due to COVID)

2019 Symposium, Institute for Psychiatric Services: The Mental Health Services Conference, Institute for Psychiatric Services, NY, US. “Improving the Care and Outcomes of Individuals with Early Psychosis: A Focus on Reducing the Duration of Untreated Psychosis”

1

2018 Symposium, 11th International Conference on Early Intervention in Mental Health, International Early Psychosis Association (IEPA), Boston, US. “Mindmap – A Quasi-Experimental Test of Early Detection of Psychosis in the U.S.”

NIMH Science to Service Symposium, American Psychiatric Association (APA), Annual Conference, New York, USA. ‘MindMap: An early detection campaign to reduce duration of untreated psychosis.’

2017 Symposium, American Public Health Association (APHA) annual meeting, Atlanta, GA, USA: “Using Media and Marketing to shorten Duration of Untreated Psychosis (DUP) in a U.S. Region**.**”

 Oral session, International Congress of Schizophrenia Research (ICOSR), San Diego, CA, USA: “Mindmap – A Population based approach to Early Detection of Psychosis in the U.S.”

2016 Symposium, 5th Biennial Schizophrenia International Research Society (SIRS) Conference, Florence, Italy: “The Step-ED Project: A Population Based Approach to Early Intervention for Psychosis.”

 Oral session, 7th International Conference on Schizophrenia Research (ICONS) of the Schizophrenia Research Foundation (SCARF), Chennai, India: “Mindmap: A campaign to reduce delays to care.”

 Oral session, 10th International Conference on Early Intervention in Mental Health, International Early Psychosis Association (IEPA), Milan, Italy. “The PEPPNET Treatment Workgroup for Early Intervention Services.”

2014 Oral session, 6th International Conference on Schizophrenia Research (ICONS) of the Schizophrenia Research Foundation (SCARF), Chennai, India: “Reducing the duration of untreated psychosis in the U.S.”

 Co-organizer of the first Young Investigators Workshop Bi-annual Schizophrenia Research Foundation (SCARF) conference, Chennai, India.

2012 Oral session, 5th International Conference on Schizophrenia Research (ICONS) of the Schizophrenia Research Foundation (SCARF), Chennai, India: Early Intervention for Psychosis in the U.S. Public Sector

2011 Oral session, International Congress of Schizophrenia Research (ICOSR), Colorado Springs, CO, USA: “Cardiovascular Risk in a First-Episode Psychosis Sample: A ‘Critical Period' for Prevention?”

 Oral session, Annual National Conference of the Indian Psychiatric Society (ANCIPS), New Delhi, India: “First Episode Psychosis and Early Intervention.”

2008 Oral session, Initiating a First-Episode Clinic in the U.S. Public Health Sector: The First Two Years Experience. International Early Psychosis Association, Melbourne, Australia.

2005 Oral session, Gained in Translation: ‘Evidence Based Medicine (EBM) Meets Psychiatric Training. 34th Annual Meeting of American Association of Directors of Psychiatric Residency Training (AADPRT), Tucson, AZ.

**Professional Service**

**Peer Review Groups/ Grant Study Sections**

2024 Invited expert, Institute for Clinical and Economic Review (ICER), Public policy meeting on KarXT for Schizophrenia

2019 Judge, National Mental Health Hackathon, Yale School of Medicine

2017-present Member, *Virtual Triage Team* of National Association of State Mental Health Program Directors Research Institute (NASMPHD-NRI) for SAMHSA Mental Health Block Grant 10% Set-Aside for first-episode psychosis

2016 Member, Program Committee for Schizophrenia International Research Society (SIRS) 2018 Biennial Conference.

2015-18 Co-chair, Treatment Workgroup, Prodrome and Early Psychosis Program Network (PEPPNET), USA

2015-2018 Standing Member, Mental Health Services Research Study Section, NIMH

2014 Ad hoc Member Mental Health Services Research Study Section, NIH/NIMH

2013-2014 Member, Special Emphasis Panel for ZMH1 ERB-I 03 R, Improving Health and Reducing Premature Mortality in People with Severe Mental Illness NIH/NIMH

2009 Member, Special Emphasis Panel/Scientific Review Group, 2009/10 ZRG1 HDM-G, NIH/NIMH

**Journal Service**

2024- Guest Editor, Special Issue on Learning Health Systems for Frist-Episode Psychosis, Schizophrenia Research

2018 - Member, Editorial Board, Schizophrenia Research

2005- Sentinel reviewer for McMaster Online Rating of Evidence (MORE) system

2005- *Ad hoc* reviewer for: JAMA Psychiatry, Cochrane Schizophrenia Review Group, New England Journal of Medicine, Academic Psychiatry, Journal of the American Medical Association, Journal of Clinical Psychiatry, Journal of the American Association of Child and Adolescent Psychiatry, Primary Care Psychiatry, BMJ Point of Care, Asian Journal of Psychiatry, Psychiatric Services, Schizophrenia Bulletin, Schizophrenia Research

**Professional Service for Professional Organizations:**

 ***Society of Biological Psychiatry (SOBP)***

 2016 - Member

 ***Schizophrenia International Research Society (SIRS)***

2015- Member

 ***Connecticut State Medical Society (CSMS)***

 2014- Member

 ***New Haven County Medical Association (NHCMA)***

 2014- Member

 ***American Association of Directors of Psychiatric Residency Training (AADPRT)***

 2009- 2019 Member

 ***U.K. Foundation Program Office*** on faculty development initiatives

2009 Advisor

 ***Center for Evidence Based Medicine (CEBM), Oxford, U.K.***

2005- Member

 ***International Early Psychosis Association (IEPA), Parkville, Australia.***

2005- Member

**Yale University Service:**

2013-present Fellow, Davenport College, Yale University

**Medical School Committees**

2018-21 Member, Yale Medicine Value-Based Payment Programs: Clinical Operations Committee

2017-19 Member, Executive Sub-committee, Graduate Medical Education Committee (GMEC), Yale Medical School / YNHH

2009-19 Member, Graduate Medical Education Committee (GMEC), Yale Medical School / YNHH

2010-13 Member, Biostatistics Curriculum Committee (Yale Medical School)

2008-2009 Member, Dean’s Search Committee for Director, Connecticut Mental Health Center

**Departmental Committees**

2014-19 Chair, Curriculum Competence Committee, Yale Psychiatry Residency Program

2009-19 Member, Graduate Education Committee, Yale Psychiatry Residency Program

**Hospital Boards & Committees**

2022-‘24 Member, Peer Review Committee, Connecticut Mental Health Center (CMHC)

2019-‘20 Senior Leadership Committee, CMHC

2008-2017 Member, Pharmacy & Therapeutics Committee, CMHC

2005-2008 Member, Peer Review Committee CMHC

**Public Service**

2020- Academic Advisory Board, Silver Hill Hospital, Connecticut

2019-22 Board of Directors, National Alliance for the Mentally Ill (NAMI), Connecticut

2015-18 Board of Directors, BH Care, *non-profit behavioral health care provider serving the Lower Naugatuck Valley, Greater New Haven, and Shoreline communities.*

1999- Member, Asha for Education (Yale chapter). *A non-profit focused on improving access and quality of primary education in India.*

**Bibiliography:**

**Peer-Reviewed Original Research**

1. Abi-Saab WM, Maggs DG, Jones T, Jacob R, **Srihari V**, Thompson J, Kerr D, Leone P, Krystal JH, Spencer DD, During MJ, Sherwin RS. Striking differences in glucose and lactate levels between brain extracellular fluid and plasma in conscious human subjects: effects of hyperglycemia and hypoglycemia. *Journal of Cerebral Blood Flow and Metabolism*. 2002; 22(3):271-9.
2. **Srihari VH**, Tek C, Chwastiak LA, Woods SW, Steiner JL. Surveillance and management of diabetes in a community mental health center population. *Psychiatric Services*. 2007; 58(9):1151-3
3. Furtado VA, **Srihari V**. Atypical antipsychotics for people with both schizophrenia and depression. *The Cochrane Database of Systematic Reviews*. 2008 (updated in 2009), Issue 1. Art. No.: CD005377. DOI: 10.1002 /14651858.CD005377.pub2.
4. Saksa JR, Cohen SJ, **Srihari VH**, Woods SW. Cognitive Behavior Therapy for Early Psychosis: A Comprehensive Review of Individual vs. Group Treatment Studies. *International Journal of Group Psychotherapy*. 2009; 59(3): 357-383.
5. Breitborde NJK, **Srihari VH**, Woods SW. Review of the operational definition for first-episode psychosis. *Early Intervention in Psychiatry*. 2009; 3(4):259–265.
6. Breitborde NJK, Woods SW, **Srihari VH**. Multifamily psychoeducation for first-episode psychosis: A cost-effectiveness analysis. *Psychiatric Services*. 2009; 60:1477-1483.
7. Furtado VA, **Srihari V**, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. *Schizophrenia Bulletin*. 2009;35(2):297-298.
8. **Srihari VH**, Breitborde NJK, Pollard J, et al. Public-academic partnerships: early intervention for psychotic disorders in a community mental health center. *Psychiatric Services*. 2009;60(11):1426-1428.
9. Breitborde NJK, **Srihari VH**, Addington D, Woods SW. Mediators and moderators in early intervention research. *Early Intervention in Psychiatry* 2010; 4(2): 143-152.
10. Phutane VH, Tek C, Chwastiak L, Ratliff JC, Ozyuksel B, Woods SW, **Srihari VH**. Cardiovascular risk in a ﬁrst-episode psychosis sample: A ‘critical period’ for prevention? *Schizophrenia Research* 2011; 127: 257-261.
11. Dodds TJ, Phutane VH, Stevens BJ, Woods SW, Sernyak MJ, **Srihari VH**. Who is paying the price? Loss of insurance coverage early in psychosis. *Psychiatric Services* 2011; 62(8):878-881.
12. Palmese LB, DeGeorge PC, Ratliff JC, **Srihari VH**, Wexler BE, Krystal AD, Tek C. Insomnia is frequent in schizophrenia and associated with night eating and obesity. *Schizophrenia Research* 2011; 133 (1-3): 238-243.
13. Breitborde NJK, Kleinlein P, **Srihari VH**. Self-determination and first-episode psychosis: associations with symptomatology, social and vocational functioning, and quality of life. *Schizophrenia Research* 2012; 137 (1-3):132-136.
14. Perez, V.B., Ford, J.M., Roach, B.J., Woods, S.W., McGlashan, T.H., **Srihari, V.H.**, Loewy, R.L., Vinogradov, S., Mathalon, D.H., 2012. Error monitoring dysfunction across the illness course of schizophrenia. *Journal of Abnormal Psychology.* 121 (2) 372-387.
15. **Srihari, V.H.**, Shah, J., Keshavan, M.S., 2012. Is early intervention for psychosis feasible and effective? *Psychiatric Clinics of North America.* 35 (3) 613-631.
16. **Srihari VH**, Phutane VH, Ozkan B, et al. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. *Schizophrenia Research* 2013;146(1-3):64–68.
17. Perez, V. B., Roach, B. J., Woods, S. W., **Srihari, V. H.**, McGlashan, T. H., Ford, J. M., & Mathalon, D. H. (2013). Early auditory gamma-band responses in patients at clinical high risk for schizophrenia. *Supplements to Clinical Neurophysiology*, 62, 147–162.
18. Ratliff JC, Palmese LB, Reutenauer EL, **Srihari VH**, Tek C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. *Psychosomatics*; 2013 Jan;54(1):67–73.
19. Fryer SL, Woods SW, Kiehl KA, Calhoun VD, Pearlson GD, Roach BJ, Ford JM, **Srihari VH**, McGlashan TH, Mathalon DH. Deficient Suppression of Default Mode Regions during Working Memory in Individuals with Early Psychosis and at Clinical High-Risk for Psychosis. *Frontiers in Psychiatry*; 2013;4:92–2.
20. Tek C, Palmese LB, Krystal AD, **Srihari VH**, DeGeorge PC, Reutenauer EL, Guloksuz S. The impact of Eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. *Schizophrenia Research* 2014;160(1-3):180-185.
21. Breitborde NJK, Kleinlein P, **Srihari VH**. Causality Orientations among Individuals with First-Episode Psychosis. *Psychosis*. 2014;6(2):177–80. PMCID: PMC4072321
22. Perez VB, Woods SW, Roach BJ, Ford JM, McGlashan TH, **Srihari VH**, Mathalon DH. Automatic Auditory Processing Deficits in Schizophrenia and Clinical High-Risk Patients: Forecasting Psychosis Risk with Mismatch Negativity. *Biological Psychiatry*. 2014 Mar 15;75(6):459–69. PMCID: PMC4028131
23. Annamalai A, Palmese LB, Chwastiak LA, **Srihari VH**, Tek C. High Rates of Obstructive Sleep Apnea Symptoms Among Patients with Schizophrenia. *Psychosomatics*. 2015; 56(1):59–66.
24. Hay RA, Roach BJ, **Srihari VH**, Woods SW, Ford JM, Mathalon DH. Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients. *Biological Psychology*. 2015; 105:130–137.
25. van Schalkwyk GI, Davidson L, **Srihari V**. Too Late and Too Little: Narratives of Treatment Disconnect in Early Psychosis. *Psychiatric Quarterly*. 2015:1–12.
26. **Srihari VH**, Tek C, Kucukgoncu S, Phutane VH, Breitborde NJK, Pollard J, Ozkan B, Saksa J, Walsh BC, Woods SW. First-Episode Services for Psychotic Disorders in the U.S. Public Sector: A Pragmatic Randomized Controlled Trial. *Psychiatric Services*. 2015; 66(7):705–12. PMCID: PMC4490067
27. Tek C, Kucukgoncu S, Guloksuz S, Woods SW, **Srihari VH**, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. *Early Intervention in Psychiatry*. 2016 Jun;10(3):193-202.
28. Altinoz MA, Ince B, Tek C, **Srihari VH**, Guloksuz S. The NF-κB signaling pathway: an important therapeutic target in psychiatric disorders. *Molecular Psychiatry*. 2016;51:239. doi:10.1038/mp.2016.207.
29. Guloksuz S, Li F, Tek C, Woods SW, McGlashan T, Friis S, **Srihari VH**. Analyzing the Duration of Untreated Psychosis: Quantile Regression. *JAMA Psychiatry*. 2016;73(10):1094-1095.
30. Starc M, Murray JD, Santamauro N, Savic A, Diehl C, Cho Y, **Srihari VH**, Morgan P, et al. Schizophrenia is associated with a pattern of spatial working memory deficits consistent with cortical disinhibition. *Schizophrenia Research* 2017 Mar;181:107-116.
31. Foss-Feig JH, Adkinson BD, Ji JL, Yang G, **Srihari VH**, McPartland J, et al. Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders. *Biological Psychiatry*. 2017;81(10):848-861.
32. Fryer SL, Roach BJ, Ford JM, Donaldson KR, Calhoun VD, Pearlson GD, Kiehl KA, **Srihari VH**, McGlashan TH, Woods SW, Mathalon DH. Should I Stay or Should I Go? FMRI Study of Response Inhibition in Early Illness Schizophrenia and Risk for Psychosis. *Schizophrenia Bulletin* 2018; 2019 Jan 1;45(1):158-168.
33. Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig T, Nordentoft M, **Srihari VH**, Guloskuz S, Hui CLM, Chen EYH, Valencia M, Juarez F, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estrogg SE, Robinson J, Penn D, Severe J, Kane JM. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. *JAMA Psychiatry*. 2018 Jun 1;75(6):555-565.
34. Cho YT, Lam NH, Starc M, Santamauro N, Savic A, Diehl C, Schleifer CH, Moujaes F, **Srihari VH**, Repovs G, Murray JD, Anticevic A. Effects of Reward on Spatial Working Memory in Schizophrenia. *Journal of Abnormal Psychology* 2018 Oct;127(7):695-709.
35. Mathis WS, Woods S, **Srihari V**. (2018). Blind Spots: Spatial analytics can identify nonrandom geographic variation in first episode psychosis program enrollments. *Early Intervention in Psychiatry*, 2018 Dec;12(6):1229-1234
36. Kline ER, DeTore NR, Keefe K, Seidman LJ, **Srihari VH**, Keshavan MS, Guyer M. Development and validation of the client engagement and service use scale: A pilot study. *Schizophrenia Research*. 2018 Nov;201:343-346.
37. Murphy SM, Kucukgoncu S, Bao Y, Li F, Tek C, Breitborde NJK, Guloksuz S, Phutane VH, Ozkan B, Pollard J, Cahill J, Woods SW, Cole RA, Schoenbaum M, **Srihari VH**. An Economic Evaluation of Coordinated Specialty Care (CSC) Services for First-Episode Psychosis in the U.S. Public Sector. *The Journal of Mental Health Policy and Economics*. 2018 Sep 1;21(3):123-130.
38. Kucukgoncu S, Kosir U, Zhou E, Sullivan E, **Srihari VH**, Tek C. Glucose Metabolism Dysregulation at the Onset of Mental Illness is not Limited to First Episode Psychosis: A Systematic Review and Meta-Analysis. *Early Intervention in Psychiatry.* 2018 Oct 2. doi: 10.1111/eip.12749. [Epub ahead of print]
39. Kang C, Zhou H, Yang J, Yang R, Sun N, Wang S, Wang S, Yang C, Han D, **Srihari VH**. Course, outcome and diagnosis stability of early-onset schizophrenia in Yunnan Province, China-a three years follow-up study. *Psychiatry Research*. 2018 Nov 7;271:144-149. [Epub ahead of print]
40. Ferrara M, TedeschiniE, BaccariF, MusellaV, VaccaF, MazziF, FerriM, **SrihariVH** & StaraceF. Early Intervention Service for first episode psychosis in Modena, Northern Italy: the first hundred cases. *Early Intervention in Psychiatry*. 2019 Jan 22. doi: 10.1111/eip.12788. [Epub ahead of print]
41. Kamens S, Davidson L, Hyun E, Jones N, Morawski J, Kurtz M, Pollard J, van Schalkwyk G, **Srihari VH**. The Duration of Untreated Psychosis: A Phenomenological Study. Psychosis. 2018; 10(4), 307–18.
42. Hamilton H. K., Woods, S. W., Roach, B. J., Llerena, K., McGlashan, T. H., **Srihari, V. H.**, Ford, J. M., & Mathalon, D. H. Auditory and visual oddball stimulus processing deficits in schizophrenia and the psychosis risk syndrome: Forecasting Psychosis Risk with P300. *Schizophrenia Bulletin*. 2018 Dec 8. doi: 10.1093/schbul/sby167. [Epub ahead of print]
43. Ferrara M, Guloksuz S, Li F, Burke S, Tek C, Frii S, Hegelstad WTV, Joa I, Johannessen JO, Melle I, Simonsen E, **Srihari VH**. Parsing the impact of early detection on duration of untreated psychosis (DUP): Applying quantile regression to data from the Scandinavian TIPS study. *Schizophrenia research*. 2019;210:128-134. doi:10.1016/j.schres.2019.05.035
44. Pollard, J. M., Ferrara, M., Lin, I.-H., Kucukgoncu, S., Wasser, T., Li, F. & Srihari, V. H., (2020), Analysis of Early Intervention Services on Adult Judicial Outcomes, *JAMA Psychiatry*, vol. 77, n°8, p. 871–872.
45. Sykes, L. A. Y., Ferrara, M., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., … Woods, S. W., (2020), Predictive validity of conversion from the clinical high risk syndrome to frank psychosis, *Schizophrenia Research*, vol. 216, p. 184–191.
46. Fortgang, R. G., Srihari, V. & Cannon, T. D., (2020), Cognitive effort and amotivation in first-episode psychosis., *Journal of Abnormal Psychology*, vol. 129, n°4, p. 422–431.
47. Trevisan, D. A., Foss-Feig, J. H., Naples, A. J., Srihari, V., Anticevic, A. & McPartland, J. C., (2020), Autism Spectrum Disorder and Schizophrenia Are Better Differentiated by Positive Symptoms Than Negative Symptoms, *Frontiers in Psychiatry*, vol. 11, p. 27.
48. Zhu, M., Ferrara, M., Tan, W., Shang, X., Syed, S., Zhang, L., … Liu, Z., (2020), Drug-naïve first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China, *Early Intervention in Psychiatry*.
49. Williams, J. C., Harowitz, J., Glover, J., Tek, C. & Srihari, V., (2020), Systematic review of racial disparities in clozapine prescribing, *Schizophrenia Research*.
50. Goetzl EJ, Srihari VH, Guloksuz S, Ferrara M, Tek C, Heninger GR. Decreased mitochondrial electron transport proteins and increased complement mediators in plasma neural-derived exosomes of early psychosis. *Transl Psychiat*. 2020;10(1):361. doi:10.1038/s41398-020-01046-3
51. Weiss, A., Chaudhry, S., Cahill, J. D. & Srihari, V. H., (2021), Establishing the Early Psychosis Intervention Clinic, New Orleans (EPIC-NOLA): Sustainability Challenges Threaten Clinical Success, *Journal of Health Care for the Poor and Underserved*, vol. 32, n°1, p. 8–17.
52. Goetzl E, **Srihari VH**, ….Heninger G. Neural cell-derived plasma exosome protein abnormalities implicate mitochondrial impairment in first episodes of psychosis. FASEB.
53. K. Gallagher, M. Ferrara, J. Pollard, L. Y. Sykes, F. Li, S. Imetovski, J. Cahill, W. Mathis, V. H. Srihari, Taking the next step: Improving care transitions from a first-episode psychosis service. *Early Interv Psychia* (2021), doi:10.1111/eip.13127.
54. Ferrara, M., Guloksuz, S., Mathis, W. S., Li, F., Lin, I.-H., Syed, S., … Srihari, V. H., (2021), First help-seeking attempt before and after psychosis onset: measures of delay and aversive pathways to care, *Social Psychiatry and Psychiatric Epidemiology*, vol. 56, n°8, p. 1359–1369.
55. M. R. Altschuler, D. A. Trevisan, J. M. Wolf, A. J. Naples, J. H. Foss-Feig, V. H. Srihari, J. C. McPartland, Face perception predicts affective theory of mind in autism spectrum disorder but not schizophrenia or typical development. *J. Abnorm. Psychol.* **130**, 413–422 (2021).
56. Goetzl EJ, Wolkowitz OM, **Srihari VH**, Reus VI, Goetzl L, Kapogiannis D, Heninger GR, Mellon SH. Abnormal levels of mitochondrial proteins in plasma neuronal extracellular vesicles in major depressive disorder. *Molecular Psychiatry*. 2021 Sep 1. doi: 10.1038/s41380-021-01268-x. Online ahead of print.
57. **Srihari VH**, Ferrara M, Li F, et al. Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial, *Schizophrenia Bulletin Open*, Volume 3, Issue 1, January 2022, sgab057, <https://doi.org/10.1093/schizbullopen/sgab057>
58. Kline, E. R. *…***Srihari VH***.* Timing of cannabis exposure relative to prodrome and psychosis onset in a community-based first episode psychosis sample. *J Psychiatr Res* **147**, 248–253 (2022).
59. Ferrara M, Gallagher K, Yoviene Sykes LA, Markovich P, Li F, Pollard JM, Imetovski S, Cahill J, Guloksuz S, Srihari VH. Reducing Delay From Referral to Admission at a U.S. First-Episode Psychosis Service: A Quality Improvement Initiative. Psychiatr Serv. 2022 Jun 2:appips202100374. doi: 10.1176/appi.ps.202100374. Epub ahead of print. PMID: 35652190.
60. Han, G. T., Trevisan, D. A., Foss-Feig, J., **Srihari, V**. & McPartland, J. C. Distinct Symptom Network Structure and Shared Central Social Communication Symptomatology in Autism and Schizophrenia: A Bayesian Network Analysis. *J Autism Dev Disord* 1–12 (2022) doi:10.1007/s10803-022-05620-0.
61. Goetzl, E. J., Srihari, V. H., Mustapic, M., Kapogiannis, D. & Heninger, G. R. Abnormal levels of mitochondrial Ca2+ channel proteins in plasma neuron-derived extracellular vesicles of early schizophrenia. *Faseb J* **36**, e22466 (2022).
62. Greene, A. S. *et al.* Brain–phenotype models fail for individuals who defy sample stereotypes. *Nature* 1–10 (2022) doi:10.1038/s41586-022-05118-w.
63. Naples AJ, Foss-Feig JH, Wolf JM, Srihari VH, McPartland JC. Predictability modulates neural response to eye contact in ASD Molecular Autism 2022, 13: 42. PMID: 36309762, PMCID: PMC9618208, DOI: 10.1186/s13229-022-00519-0.
64. Breitborde N, Parris C, Stearns W, Nawaz S, Seiber E, Hamilton S, Hefner J, Hogan T, Singh P, Knudsen K, Martt N, Srihari V, Cahill J, Jani A, Anagbonu F, Baughman C, Carpenter K, Dunivant C, Dunlap N, Guirgis H, Lazarus S, Moe A, Nguyen C, Wastler H, Montesano V. Promoting the Success and Sustainability of Coordinated Specialty Care Teams in Ohio. Psychiatric Services 2022, appips20220126. PMID: 36415991, DOI: 10.1176/appi.ps.20220126.
65. Mathis WS, Ferrara M, Burke S, et al.: Granular analysis of pathways to care and durations of untreated psychosis: A marginal delay model. Plos One 2022; 17:e0270234
66. Hagler M, Ferrara M, Yoviene Sykes L, Li F, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Perkins D, Mathalon D, Seidman L, Tsuang M, Walker E, Powers A, Allen A, Srihari V, Woods S. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis Schizophrenia Research 2023, 255: 239-245. PMID: 37028205, PMCID: PMC10207144, DOI: 10.1016/j.schres.2023.03.047.
67. Szmulewicz A, et al., Antipsychotic drugs in first-episode psychosis: A target trial emulation using the FEP-CAUSAL Collaboration. American Journal of Epidemiology, 2023
68. Ferrara M, Guloksuz S, Hazan H, et al. The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service. *Schizophr Res*. 2023;260:198-204. doi:10.1016/j.schres.2023.08.005
69. Hauke DJ, Charlton CE, Schmidt A, et al. Aberrant Hierarchical Prediction Errors Are Associated With Transition to Psychosis: A Computational Single-Trial Analysis of the Mismatch Negativity. *Biol Psychiatry: Cogn Neurosci Neuroimaging*. 2023;8(12):1176-1185. doi:10.1016/j.bpsc.2023.07.011
70. Benrimoh D, Dlugunovych V, Wright AC, et al. On the proportion of patients who experience a prodrome prior to psychosis onset: A systematic review and meta-analysis. *Mol Psychiatry*. Published online 2024:1-21. doi:10.1038/s41380-024-02415-w
71. Venkataraman S, Hazan H, Li F, et al. Role of Early Psychosis Detection in the Relationship Between Personal Income and Duration of Untreated Psychosis. *Psychiatr Serv*. 2024;75(5):427-433. doi:10.1176/appi.ps.20230239
72. Hazan H, Ferrara M, Riley S, et al. The impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction. Schizophr Res. 2024;264:457-461. doi:10.1016/j.schres.2024.01.022
73. Wannan C, et al., Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis*.*
74. Ferrara M, Basaldella M, Vacca F, et al. The Italian adaptation of the Mini-SIPS, a tool for early detection of individuals at clinical high risk and first episode of psychosis: A preliminary study of implementation in an Italian FEP program. *Early Interv Psychiatry*. Published online 2024. doi:10.1111/eip.13548

Bottom of Form

**Study Protocols**

1. Tek C, Guloksuz S, **Srihari VH**, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. *BMC Psychiatry*. 2013; 13:176
2. **Srihari VH**, Tek C, Pollard J, Zimmet S, Keat J, Cahill JD, Kucukgoncu S, Walsh BC, Li F, Gueorguieva R, Levine N, Mesholam-Gately RI, Friedman-Yakoobian M, Seidman LJ, Keshavan MS, McGlashan TH, Woods SW. Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. *BMC Psychiatry*. 2014;14(1):335

**Chapters, Books, and Reviews**

1. Martin A, **Srihari VH**. Geometrically Evident: Framing Studies Using the Graphic Appraisal Tool for Epidemiology (GATE). *Journal of the Academy of Child and Adolescent Psychiatry*. 2006; 45(12):1521-6.
2. **Srihari V**, Martin A. Gained in Translation: Evidence-Based Medicine (EBM) Meets Pediatric Psychopharmacology. *Child and Adolescent Psychiatric Clinics of North America.* 2006; 15(1):263-87.
3. **Srihari VH**. Evidence-Based Mental Health Care. *Evidence-Based Medicine*. 2007; 12:124-125.
4. **Srihari VH**. Better. *New England Journal of Medicine*. 2008; 358(7):755-756.
5. **Srihari VH**. Statistics Workbook for Evidence-based Healthcare. *Evidence Based Medicine/ ACP Journal Club*. 2009; 14(3): 93.
6. **Srihari VH**. Evidence-Based Medicine (EBM) in the Education of Psychiatrists. *Academic Psychiatry*. 2008;32(6):463-9.
7. Breitborde NJK, **Srihari VH**. Family work for first-episode psychosis: A service delivery protocol. In Psychosis: Causes, Diagnosis and Treatment. Nova Science Publishers, Inc, NY. 2011.
8. **Srihari VH**, Lee W. Frontal lobe epilepsy and its neuropsychiatric manifestations. In T. Hurwitz & W. Lee (Eds). Casebook in Neuropsychiatry. APA 2013.
9. Pollard J, Tek C, Woods S, McGlashan T, and **Srihari, VH**. Early Intervention and Prevention for Psychotic Illnesses. In S. Jacobs & J. Steiner (Eds). Yale Textbook of Public Psychiatry, Oxford University Press, 2016.
10. Steiner JL, Anez-Nava L, Baranoski M, Cole R, Davidson L, Delphin-Rittmon M, Dike C, DiLeo PJ, Duman RS, Kirk T, Krystal J, Malison RT, Rohrbaugh RM, Sernyak MJ, **Srihari V**, Styron T, Tebes JK, Woods S, Zonana H, Jacobs SC. The Connecticut mental health center: Celebrating 50 years of a successful partnership between the state and Yale University. *Psychiatric Services*. American Psychiatric Association; 2016;67(12):1286–9.
11. Pollard JM, Cahill JD, **Srihari VH**. Building early intervention services for psychotic disorders: A primer for early adopters in the U.S. *Current Psychiatry Reviews*. 2016;12(4):350-356. doi:10.2174/1573400512666160927142133.
12. Wasser T, Pollard J, Fisk D, **Srihari V**. First-Episode Psychosis and the Criminal Justice System: Using a Sequential Intercept Framework to Highlight Risks and Opportunities. *Psychiatr Serv*. 2017;68(10):994-996. doi:10.1176/appi.ps.201700313.
13. Dixon LB, Goldman H, **Srihari VH**, Kane JM. Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. *Annual Review of Clinical Psychology*. 2018; 14:237-258.
14. Bhalla I, Tampi R, **Srihari VH** [Editors]. 50 Studies Every Psychiatrist Should Read. Oxford University Press. (2018).
15. Sun A, **Srihari VH**. QTc Interval Abnormalities and Psychotropic Drug Therapies in Psychiatric Patients. In Bhalla I, Tampi R, **Srihari VH** [Editors]. 50 Studies Every Psychiatrist Should Read. Oxford University Press. (2018).
16. Lane C, **Srihari VH**. Clozapine for Treatment-Resistant Schizophrenia. In Bhalla I, Tampi R, **Srihari VH** [Editors]. 50 Studies Every Psychiatrist Should Read. Oxford University Press. (2018).
17. Gupta N, **Srihari VH**. North American Prodrome Longitudinal Study. In Bhalla I, Tampi R, **Srihari VH** [Editors]. 50 Studies Every Psychiatrist Should Read. Oxford University Press. (2018).
18. Ferrara M, Mathis WS, Cahill JD, **Srihari VH**. Early Detection of the Schizophrenia(s): A Population Health approach. In: Intervening Early in Psychosis – a team approach, edited by K.V. Hardy, J.S. Ballon, D.L. Noordsy and S. Adelsheim. Washington DC: American Psychiatric Publishing. 2019
19. **Srihari VH**, Rohrbaugh RM. Embracing Uncertainty: A prescription toward clinical expertise. In: Resident and Training Director Handbook: A Survival Guide for Psychiatric Residency, edited by Wang R, De Golia S. Washington DC: American Psychiatric Publishing. 2023
20. Keshavan MS, **Srihari VH**, Reddy R [Editors]. Schizophrenia: A Practical Primer. Routledge (2023).
21. Uhlhaas PJ, Davey CG, Mehta UM, et al. Towards a youth mental health paradigm: a perspective and roadmap. Mol Psychiatry. 2023;28(8):3171-3181. doi:10.1038/s41380-023-02202-z

**Peer-Reviewed Educational Materials**

1. American Association of Directors of Psychiatry Residency Training (AADPRT): *Model Curriculum on Evidence-Based Mental Health.* Available at [www.aadprt.org](http://www.aadprt.org) and annually updated version on <https://classesv2.yale.edu/portal/>
2. National Association of State Mental Health Program Directors (NASHMPD): Technical assistance webinar on Methodological and Practical Issues in Population Based Programming: Incidence, Engagement, Penetration & Outreach Effectiveness. Available at <http://www.nasmhpd.org/content/methodological-and-practical-issues-population-based-programming-incidence-engagement>

**Invited Editorials and Commentaries**

1. **Srihari VH**. Bringing neuroscience to teaching rounds: Refreshing our clinical pidgin. *Asian Journal of Psychiatry*. 2015 Oct;17:138–9.
2. **Srihari VH**, Jani A, Gray M. Early Intervention for Psychotic Disorders: Building Population Health Systems. *JAMA Psychiatry*. 2016 Jan 6;73(2):1–3.
3. **Srihari VH**. Working toward changing the Duration of Untreated Psychosis (DUP). *Schizophrenia Research*. 2018 Mar;193:39-40.
4. **Srihari V. H.** and Cahill J.D. Early Intervention for Schizophrenia: Building Systems of Care for Knowledge Translation. In: Youth Mental Health: Vulnerability and Opportunities for Prevention and Early Intervention, edited by P. J. Uhlhaas and S. J. Wood. Strüngmann Forum Reports, vol. 28, J. Lupp, series editor. Cambridge, MA: MIT Press. 2019
5. Torous J, Chanen AM, Chen EYH, Do KQ, Heinssen RK, McGorry PD, Nordentoft M, Schoenbaum M, **Srihari VH**, and Verma SK. Developing and Implementing Tools for Prevention and Early Intervention. In: Youth Mental Health: Vulnerability and Opportunities for Prevention and Early Intervention, edited by P. J. Uhlhaas and S. J. Wood. Strüngmann Forum Reports, vol. 28, J. Lupp, series editor. Cambridge, MA: MIT Press. 2019.
6. **Srihari VH**, Kane JM. Early Intervention Services 2.0: Designing Systems for the Next Generation of Work. *Biol Psychiat*. 2020;88(4):291-293. doi:10.1016/j.biopsych.2019.10.00
7. Keshavan M, Ongur D, **Srihari VH**. Toward an expanded and personalized approach to Coordinated Specialty Care in early course psychoses. Schizophrenia Research. 2022 (In Press)
8. **Srihari VH**, Keshavan MS. Early Intervention Services for Schizophrenia: Looking Back and Looking Ahead. Schizophrenia Bulletin 2022 (In Press)
9. **Srihari V,** Li F. DUP redux: Observations vs. experiments in early intervention. Schizophrenia Research 2022, 251: 46-48. PMID: 36565532, DOI:10.1016/j.schres.2022.12.006.

**Case Reports, Technical Notes, Letters**

1. **Srihari VH**, Lee TS, Rohrbaugh RM, D'Souza DC. Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder. *Schizophrenia Research*. 2006; 82(2-3):261-4.
2. Kantrowitz JT, **Srihari VH**, Tek C. Three cases of risperidone-induced enuresis. *Schizophrenia Research*. 2006; 84(1):174-5.
3. Kantrowitz JT, **Srihari VH**, Tek C. Resolution of Tardive Dyskinesia After Addition of Aripiprazole to HaloperidolDepot. *Journal of Clinical Psychopharmacology*. 2007;27(5):525-6.
4. **Srihari VH**, Lee WT. Evidence-Based Case Report: Pulmonary embolism in a patient taking Clozapine. *British Medical Journal*. 2008; 336(7659):1499-501.
5. Tek C, **Srihari V**, Tek E. Successful Acamprosate treatment of alcohol dependence in schizophrenia. *Schizophrenia Research*. 2008;106(2-3):373.
6. Westphal A, Bloch MH, **Srihari VH**. Evidence-Based Case Report: Prescribing for a Young Adult with Inattention and Probable Stimulant-Induced Psychosis. *The Residents’ Journal (APA)*. 2009; 7(4):9-12.
7. Ozkan B, Phutane V, Jonas E, Tek C, **Srihari VH**. Hoofbeats and Zebras: Neurodegenerative disorder presenting as a 'first-episode' of psychosis. *General Hospital Psychiatry*. 2011; 33(4): 412.e1-3.
8. Ferrara M, **Srihari VH**. Early Intervention for Psychosis in the United States: Tailoring Services to Improve Care for Women. *Psychiatr Serv*. Published online 2020:appi.ps.2020002. doi:10.1176/appi.ps.202000205
9. Srihari VH, Guloksuz S, Friis S. Natural History, Not Lead Time. *Am J Psychiat*. 2020;177(12):1185-1185. doi:10.1176/appi.ajp.2020.20040402

**Preprint for Scholarship in review**

Mathis WS, Ferrara M, Cahill J, Karmani S, Tayfur SN, Srihari V. TimelinePTC: Development of a unified interface for pathways to care collection, visualization, and collaboration in first episode psychosis. arXiv. Published online 2024. doi:10.48550/arxiv.2404.12883

Nicholls-Mindlin J, Hazan H, Zhou B, et al. The Anomalous Effect of COVID-19 Pandemic Restrictions on the Duration of Untreated Psychosis (DUP). medRxiv. Published online 2024:2024.05.09.24306737. doi:10.1101/2024.05.09.24306737